What monitoring schedule is used for Cosentyx (secukinumab)?
Cosentyx (secukinumab) monitoring is typically based on two things: (1) your baseline screening before starting and (2) clinical follow-up after each stage of therapy (especially around when you first start or when symptoms change). The exact schedule can vary by your condition (psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis) and by clinician preference.
The key baseline checks are usually focused on infection risk, including tuberculosis screening, because biologics that block IL-17 can increase the risk of serious infections. Ongoing monitoring then tends to center on whether you develop signs of infection, and on safety/tolerability issues that show up after treatment begins.
What baseline tests are usually done before starting Cosentyx?
Before the first dose, clinicians generally check:
- Tuberculosis (TB) status (screening is standard for biologics of this type).
- Infection status (looking for any active infection before starting).
- Vaccination status (because live vaccines are typically avoided during biologic therapy).
How often are follow-up visits typically scheduled after starting?
Common real-world practice is periodic follow-up visits shortly after initiation and then at intervals aligned with disease control and symptom monitoring. Your prescriber may also review:
- Infection symptoms (fever, persistent cough, worsening sores, etc.).
- Response milestones (pain, stiffness, skin clearance).
- Any new adverse effects.
The dosing schedule for Cosentyx itself may guide how quickly clinicians assess whether the treatment is working, but the “monitoring schedule” is usually symptom- and risk-driven rather than a single fixed calendar for all patients.
Do you need lab monitoring (bloodwork) on Cosentyx?
For Cosentyx specifically, routine lab monitoring is not typically the same kind of mandatory, fixed lab schedule you see with some other systemic therapies. Many clinicians focus on infection screening and clinical monitoring, and order labs when there’s a specific reason (for example, if another condition or medication makes it necessary).
What should prompt extra monitoring?
You should seek medical advice promptly (and your clinician may adjust the monitoring plan) if you develop:
- Signs of infection (especially fever or symptoms that don’t improve).
- New or worsening respiratory symptoms.
- Any serious adverse reaction.
Where to check the exact monitoring language for your situation
For the most precise, label-level safety and monitoring requirements, you’ll want to review your local prescribing information and your dermatologist/rheumatologist’s protocol for your diagnosis.
If you want, tell me which condition you’re taking Cosentyx for (plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis) and whether you’re asking about baseline TB screening, visit frequency, or lab tests. I can then narrow the answer to the monitoring type most relevant to your use case.